Process for preparation benzamide derivatives

专利摘要:
Amide-compounds represented by the formula (I): <CHEM> wherein R1 represents hydrogen, lower alkoxy, hydroxy, lower alkyl, halogen, amino which can be substituted by lower alkyl, nitro, cyano, sulfamoyl which can be substituted by lower alkyl, R2 represents hydrogen, lower alkoxy, hydroxy, lower alkyl, halogen, amino, nitro, wherein R1 and R2 can be combined to form methylenedioxy, R3 means hydrogen, lower alkyl, halogen, or amino, R4 and R5 may be the same or different and each represents lower alkyl or wherein R4 and R5 may be combined together with nitrogen to form 1-pyrrolidinyl or piperidino, and pharmacologically-acceptable acid-addition salts thereof, which exhibit excellent effects in the activation of gastric motor function, a process for preparation pharmaceutical compositons thereof, as well as a method for the treatment of a subject suffering from an ailment associated with inadequate gastric motor function by administrating such a compound to the said subject, are all disclosed.
公开号:SU1627082A3
申请号:SU4356531
申请日:1988-09-02
公开日:1991-02-07
发明作者:Итох Ясуо；Като Хидео；Косинака Еиити；Огава Нобуо；Нисино Хироюки；Сакагути Дзун
申请人:Хокурику Фармасьютикал Ко, Лтд (Фирма)；
IPC主号:

专利说明:

The invention relates to organic chemistry, namely to a method for producing benzamide of the general formula
Rl.R
Q-CONHCH2-C / OCH7Ctl2N ×
Where
R
R (is hydrogen, lower alkoxy, 1-roxy, lower alkyl, i.i inR:
d
gene, amino, nitro, cyano, sulfamoyl, which may be substituted by lower alkyl;
R is hydrogen, low alkoxn, hydrocgly, halogen, amino, nitro, or P 4 and Rj can together form a methylenedioxy group;
R "is hydrogen, lower alkyl,
halogen, amino R. and R (same or different)
each is lower alkyl, or R. and Ry together with the nitrogen atom can form a 1-pyr rolidinyl or piperidino group, which dare the ability to activate gastric motor function and can therefore be used in medicine. The invention is the development of an available method for producing compounds with the ability to activate gastritis function.
Reference Example 1. (Dimethyl amino) ethoxy benzaldehyde.
To a solution of 61.1 g of p-hydroxybenzaldehyde in 240 ml of M, M-dimethylformamide, 138 g of potassium carbonate, 80.7 g of 2-dimethylaminoethyl chloride and 30 ml of isopropyl ether are added. The mixture was stirred at 60 ° C for 1.5 hours. After cooling, the reaction mixture was poured into 720 ml of water and everything was extracted with chloroform. The chloroform layer is extracted with aqueous hydrochloric acid. The aqueous layer was basified with an aqueous solution of sodium hydroxide and extracted with ethyl acetate. The extract is washed with water, dried and evaporated. The residue is distilled to obtain 69.1 g of a colorless oil, b.p. 142-144 ° C (4 mm Hg).
NMR spectrum f (CDC13), ppm: 2.34 (6H, s), 2.76 (2H, J 6 Hz), 4.15, (2H, t, J 6 Hz), 7.02 (2H, d, J 9 Hz), 7.82 (2H, d, J 9 Hz), 9.87 (1H, s).
Reference Example 2. (1-Pyrrolidinyl) ethoxy benzaldehyde.
A mixture of 2.29 g of 4- (2-bromoethoxy) benzaldehyde, 1.42 g of pyrrolidine and 2.07 g of potassium carbonate in 8 ml of N, N-dimethylformamide is stirred at 60 ° C for 2 hours. After cooling, water is added and all extracted with ethyl acetate. The ethyl acetate layer is extracted with a solution of hydrochloric acid. The aqueous layer was basified with potassium carbonate and extracted with ethyl acetate. The extract is washed with water, dried and evaporated. The residue is distilled to obtain 1.72 g of a colorless oil. mp. 170 ° C (5 mm Hg).
NMR spectrum § (CDCl1), ppm: 1.60-2.27 (4H, m), 2.44-2.80 (4H, m), 2.93 (2H, t, L 6 Hz ), 4.19 (2H, t, J 6 Hz), 7.01 (2H, d, L 9 Hz), 7.82 (2H, d, L 9 Hz), 9.87 (1H, s).
In the same manner as described in references 1 and 2, the compound of reference 3 is prepared.
Reference Example 3. 4- (2-Piperidineethoxy) benzaldehyde: colorless oil, b.p. 160-162 ° G (6 mm Nr.).
NMR spectrum Ј (SPS1), ppm: 1.12-1.76 (6H, m), 2.27-2.61 (4n, m), 2.79 (2H, t, J 6 Hz ), 4.18 (2H, t, J 6 Gp), 7.00 (2H, d, J 9 Hz), 7.82 2H, d, J - 9 Hz), 9.87 (1H, s).
Reference Example 4. 4- (f 2-Dimethyl-amino) ethoxy benzaldoxime.
A mixture of 154 g (dimethylamino) ethoxyTbenzaldehyde and 59.9 g of hydroxylamine hydrochloride in 600 ml of ethanol is boiled for 1U min. After cooling, the precipitate is filtered to obtain the hydrochloride as light yellow crystals, b.p. 174-175 ° C. These crystals are dissolved in 150 ml of water. The solution is alkalinized with potassium carbonate and extracted with chloroform. The extract is dried and evaporated. The residue is washed with isopropyl ether to obtain 157 g of colorless crystals which are recrystallized from ethyl acetate as colorless scales, mp. 95-96 ° C.
Calculated,%: G, 63.44, H 7.74, N 12.45.
C "H BMGOg
Found, U: C 63.28; H 7.71, N 13.37.
In the same manner as described in reference 4, the compounds are prepared in reference 5 and 6.
Reference Example 5. (2-Pyrrolidinyl) ethoxy benzaldoxime hydrochloride: colorless plates, mp. 219-220.5 ° C (EtOH).
Calculated,%: C 57.67, N. 7.07, N 10.35.
C SH- | 8N2 () Z-HC1
Found: C, 57.57; H, 7.15; N, 10.25.
Reference Example 6. 4- (2-Piperidine-ethoxy) benzaldoxime hydrochloride: colorless flakes, mp. 224-225 C (EtOH).
five
Calculated,% C 59.051 H, 7.43; N 9.84.
Found,%: C 58.74; H 7.28 | N 9.64.
Reference Example 7. 4- (2-PN-peridinoethoxy) benzylamine.
A suspension of 32.3 g of 4- (2-piperidine-ethoxy) benzaldoxime in 400 ml of 10% ammonium methane is reduced over 3.6 g of the catalyst to Rane's nickel at a pressure of 50 kg / cm and at 30 C. The catalyst is filtered off and the filtrate is evaporated . The residue is distilled to obtain 27.7 g of a colorless oil, b.p. 185-190 ° C (6 mm Hg).
NMR spectrum $ (CDCl1), ppm: 1.30 1.90 (8H, m), 2.40-2.60 (4H, m), 2.76 (2H, t. J 6 Hz) , 3.79 (2H, s) 4.09 (2H, T, J 6 Hz), 6.86 (2H, d, J - 9 Hz), 7.21 (.H, l, J 9 Hz).
In the same manner as described in reference 7, the compound is prepared in reference 8 and 9.
Reference Example 8. 4- .- (1-Pnrrolidinyl) ethoxy benzylamine: a colorless oil, b.p. 163-165 ° C (3 mm Hg).
NMR Spectrum O (SPTC), ppm: 1Г53 (2H, W), 1.70-1.90 (4H, m), 2.50-2.75 (4H, m), 2.89 ( 2H, t, J - 6 Hz), 3.79 2H, s), 4.10 (2H, t, J - 6 Hz), 6.88 (2H, d, J 8 Hz), 7.22 (2H , l, J 9 Hz).
Reference Example 9. (Dimethylamino) ethoxy benzylamine: a colorless oil, mp. 142-144 ° C (6 mm Hg
NMR spectrum of P (CDCl1), ppm: 1.45 (2H, s), 2.32 (6H, s), 2.71 (2H, t, L 6 Hz), 3.79 (2H, c), 4.05 (2H, t, L 6 Hz), 6.88 (2H, d, J 9 Hz), 7.21 (2H, d, J g 9 Hz).
Example 1. N-Ј4-L2- (Dimethyl amino) ethoxy benzyl U-3,4-dimethoxybenzamide.
To a cooled solution of 20.0 g of 4- 2- (dimethylamino) ethoxy-benzyl-amine in 60 ml of toluene is added a solution of 21.7 g of 3-4-dimethoxybenzoyl chloride (which is prepared with 19.7 g of 3,4-dimethoxybenzoic acid and 38.5 g of thionyl chloride in the usual way) in 60 ml of toluene with stirring. The mixture is stirred at room temperature for 30 minutes. 120 ml of water and 1 ml of concentrated hydrochloric acid are added to the mixture. The aqueous layer is separated, dried by
70S2
Apply 20 ml of toluene with alkali and alkalinized with a 20 / Ј hydroxy solution ;; l of sodium until a precipitate forms, which is washed with isopropyl ether in the amount of 37.0 g of light brown crystals. Recrystallization of crystals
from ethanol and isopropyl ether gave the title compound as) 0 colorless needles, t.l.111-112 ° C.
Calculated, 7 ,: С 67.0; H 7.31; N 7.82.
.
Found,%: D 66.96; H 7.28; N 7.78.
Example 2. N {4-L2- (Dimethylamino) ethoxyDbenzene-3,4-dnmet hydroxybenzamide hydrochloride.
2Q A solution of 3.23 g of M- | 4- 2- (dnmethyl-amino) ethoxy benzp} -3, 4-dnmethoxy-b, enzamide p ethanol is acidified by adding a solution of hydrogen chloride in ethanol. The precipitate is filtered
25 and washed with a mixture of etapol and isopropyl ether to obtain 3.22 g of light brown crystals, which recrystallized comfort from ethanol in the form of colorless prisms, mp. 194-195 ° C.
thirty
Calcd. 7: C 60.83, H 6.89, N 7.09.
C20H26N2o, .Hc: i
Found 7; C 60.78, H 6.99; 35 N 7.05.
Example 3. 3,4-methylenedioxy-N-J4- .- (1 -pyrrolidinyl) 3TOKCHJ - -benzyl. -Benzamide.
40 To a cooled solution of 7.0.0 g of (1-pyrrolidinyl) -ethoxy benzylamine and 30 ml of chloroform were added 17.7 g of 3,4-methylenedioxybenzoyl chloride (prepared with 15.9 g
45 piperonyl acid and 65.3 g of thionyl chloride in the usual way). The mixture is stirred at room temperature for 20 minutes and the solvent is evaporated. 50 ml of water are added to the residue and the mixture is washed with ethyl acetate. The aqueous layer is alkalinized with potassium carbonate. And extracted with ethyl acetate. The extract is washed with water, dried and evaporated. The residue is washed with isopropyl ether to obtain 30.0 g of colorless crystals, which are recrystallized from ethyl acetate as colorless needles, mp 93.5-94.5.
calculated,%: N 7.60.
C2 (Hi4Na04
C, 68.46; H, 6.57;
68.44; n 6.65;
4. 2,4-Dimethoxy-M Found,%: N 7.45.
Example ...... g ..
(1-pyrrolidinyl) e goxyl benzyl-beisamide.
To a cooled suspension of 1.82 g of 2,4-dimethoxybenzoic acid in 10 ml of tetrahydrofuran was added 1.09 g of ethyl chloroformate and 1.01 g of triethylamine. After stirring for 15 minutes, a solution of 2.0 g of (1-pyrrolidinyl) ethoxyL-benzylamine in 5 ml of tetrahydrofuran is added to the mixture. The mixture is stirred for 15 minutes and the solvent is evaporated. To the residue was added 10% hydrochloric acid, and the solution was washed with ethyl acetate. The aqueous layer was basified with potassium carbonate and extracted with ethyl acetate. The extract is washed with water, dried and evaporated to give 3.31 g of the title compound as a colorless oil.
Mass spectrum m / z: 384 (M).
IR spectrum (liquid), cm: 1648 (. With 0).
NMR spectrum Ј (SPS15), ppm: 1.62-1.97 (4H, m), 2.44-2.76 (4H, m) 2.88 (2H, t, L 6 Hz) , 3.84 (ZN, s), 2.44-3.86 (ZN, s), 4.09 (2H, t, J 6 Hz), 4.58 (2H, d, L 5.5 Hz) , 6.4 (N, n, L 2 Hz), 6.59 (1H, dd, J 9.2 Hz), 6.88 (2H, d, J 9 Hz), 7 „27 (2H, d, L 9 Hz), 7.99 (1H, w), 8.21 (1H, d, J 9 Hz).
Example 5. 4-Amino-5-chloro-N- (dimethylamino) ethoxy benzyl - -2-methoxybenzamide.
To a cooled suspension of 2.49 g of 4-amino-5-chloro-2-methoxy-benzoic acid in 15 ml of chloroform are added in pp. Successively 1.26 g of three ethylamine and 1.35 g of ethyl chloroformate with stirring. The mixture was stirred at the same temperature for 30 minutes, then a solution of 2.00 4- .- (dimethylamino) ethoxy benzylamine in 10 ml of chloroform was added to the mixture while stirring. The mixture was stirred at room temperature for 14 hours and the solvent was evaporated. 10% hydrochloric acid was added to the residue and the iodine solution was washed with ethyl acetate. Water
five
0
five
the layer is alkalinized with potassium carbonate and extracted with chloroform. The extract is washed with water, dried and evaporated.
The residue is washed with ether to obtain 3.87 g of slightly brown crystals, which are recrystallized from ethanol to form colorless needles. m.p. 147-148 ° C.
0 Calculated,%: C 60.39; H 6.40, N 11.12.
C1N 03
Found,;: C, 60.28; H 6.46; N 11.12.
The free base is then converted to the hydrochloride salt in the usual way, using a solution of hydrogen chloride in ethanol, as in Example 2. Recrystallization of the hydrochloride from ethanol gives colorless needles, mp. 206.5-208 ° C.
Calculated,%: C 55.08, H 6.08, N 10.14.
S19H24S1TsrNS1
Found% C 54.86, H 6.21; N 9.98.
Example 6. (Dimethylamino) ethoxy benzit-2-methoxy-5-sulphamoyl benzamide.
To a cooled suspension of 14.3 g of 2-methoxy-5-sulphamoylbenzoic acid in 60 ml of tetrahydrofuran, 6.25 g of triethylamine and 7.45 g of methyl acetic acid chloride are added dropwise in sequence with stirring. The mixture was stirred at the same temperature for 1 hour, and then a solution of 10.0 g of 4-2-2 (dimethylamino) ethoxy-benzylamine in 40 ml of tetrahydrofuran was added dropwise with stirring. The mixture is stirred at room temperature for 14 hours and the solvent is evaporated. Hydrochloric acid (10%) is added to the residue and the aqueous solution is washed with ethyl acetate. The aqueous layer was alkalinized with potassium carbonate, and a precipitate was obtained, which was washed with water and ethyl acetate in an amount of 0 16.6 g of colorless crystals.
Recrystallization of crystals from ethanol gave the title compound as colorless needles, mp, 154-155 ° C.
Calculated,%: C 56.00; H 6.18;
0
five
0
five
N 10.31.
With „N45I, 0.8
Found; C 55.71; N 10.02.
n 6.2i;
Next, the free base is converted to the hydrochloride in the usual way. Recrystallization of methanol ich hydrochloride gave colorless needles, mp. 122.5-123 ° C.
Calculated,%: C 47.55; H 6.30; N 8.75.
C49H25N, OyS.HCl
2Hi °
The residue is added to the residue and the nio rice is washed with couplet acetate. The aqueous slurry is made alkaline with kchchi carbonate and traced with ethyl acetate. Tks | rakt washed with water, dried and evaporated. The resin was washed with ethyl acetate to obtain 1.19 g of light yellow crystals which recrystallized ich ethanol to obtain colorless crystals, m.p. 173.5-174.5 ° C.
Calculated,%: C 57.28, N 11.13.
H 6.14,
C, 8H23N,
15
57.58; H 6.40;
Found,%: C 47.471 H 5.90; About N 8,72.
Example 7. (Dnmethyl-amino) ethoxy benzyl-5-dimethylaminosulfonyl-2-methoxybenzyl.
To a cooled suspension of 3.20 g of 5-dimethylaminpsulfonyl-2-methoxyhyboenoic acid in 10 ml of tetrahydrofuran is added dropwise in succession 1.25 g of trichtilamine and 1.34 g-. . chloroformic acid-20 (dimethylamino) ethoxy benzyl ethyl ester with stirring. A mixture of perimethylamine and 1.14 g of tritylamine n 0 ml
Found,%: N 10.95.
Example 9. (Dimethyl amino) ethoxy} benzyl-4-fluorobench mid
To a cooled solution of 2.00 g
at the same temperature for 30 minutes and at a rate of 2.00 g of 4-Ј2- (dimethylamino) ethoxyPbenchilamine in 10 ml of tetragndrolluran are added
drop by stirring. The mixture is stirred at room temperature for 2 hours and the solvent is evaporated. Hydrochloric acid (10%) was added to the residue and the aqueous solution was washed with ethyl acetate. The aqueous layers were basified with potassium carbonate and extracted with ethyl acetate. The extract is dried and evaporated. The residue is washed with isopropyl ether to give 4.10 g of colorless crystals, which are recrystallized from ethyl ethyl acetate.
acetate and ether to give colorless gras, mp. 99.5-100.5 ° C.
Calculated: 7; С 57.9Г, Н 6.71; N 9.65.
C2, H29NjOrS
Found,%: C 57.69, - H 6.82; N 9.38.
Example 8. N- {4- 2- (Dimethyl-amino) ethoxy benzyl-4-sulfamylbenzamide.
To a cooled solution of 1.50 g of 4-Ј2- (dimethylamino) ethoxy | -benzylamine and 0.87 g of triethylamine in 10 ml of chloroform, 1.87 g of 4-sulimylbenzyl chloride, prepared from 1.71 g 4-sulfamylbenzoic acid with 16.3 g of thionyl chloride in the usual way with stirring. The mixture is stirred at room temperature for 30 minutes and the solvent is evaporated. Hydrochloric acid (10%)
The residue is added to the residue and the nio pores are washed with a few acetate. The aqueous slurry is made alkaline with cchci carbonate and the TCS is tragic with ethyl acetate. Tx | rkt is washed with water, dried and evaporated. The residue was washed with ethyl acetate to obtain 1.19 g of light yellow crystals, which recrystallized ich ethanol to obtain colorless crystals, m.p. 173.5-174.5 ° C.
Calculated,%: C 57.28, N 11.13.
H 6.14,
C, 8H23N,
57.58; H 6.40;
-. . (dimethylamino) ethoxy-benzyl-amine and 1.14 g of tritylamine n 0 ml
Found,%: N 10.95.
Example 9. (Dimethyl-amino) ethoxy} benzyl-4-fluorobench mid.
To a cooled solution of 2.00 g
chloroform was added 1.80 g of 4-fluorobenzoyl chloride, which was prepared from 1.59 g of 4-fluorobenzoic acid with 7.77 g of thionyl chloride. The mixture is stirred for 30 minutes and the solvent is evaporated. The hydrochloric acid (10%) is added to the residue and the aqueous solution is washed with chlacitol, the aqueous layers are made alkaline with potassium carbonate and extracted with ethyl acetate. The extract is washed with water, dried and evaporated. The residue is washed with n-hexane to obtain 3.07 g of light yellow crystals, which are recrystallized from a mixture of ethanol and ether with hto
by irradiating colorless needles. m.p. about,
113C 68.34 H 6.69;
C 68,311 N 6.67J
114 ,.
Calculated% N 8,85.
C1gH2 FNz02
Found, 7,: N 8.73.
Next, the free base is converted to the hydrochloride in the usual way. Recrystallization of hydrogen / ohloride from ethanol gives colorless plates, mp. 165-166 ° C.
Calculated,%: C, 61.27; H N 7.94.
С18н2 гкгог.нс1
6.28;
Found,%: C 61.18, H 6.29-, N 7.75. .G
Example 10. 2-AminoH4- 2- - (dnmethylamino) ethoxy benzyl-ben-amide.
To a solution of 2.00 g (dimethyl-amino) ethoxy-T-benzylamine in 20 ml of ethyl acetate, 1.04 g of isatic anhydride is added. The mixture is stirred at room temperature for 15 minutes. Hydrochloric acid (10%) is added to the mixture. The aqueous layer was separated, alkalized with potassium carbonate and extracted with ethyl acetate. The extract is washed with water, dried and evaporated. Recrystallization of the residue from ethyl acetate gives 1.85 g of colorless columns, mp.104-105 ° C,
Calculated: C 68,98; H 7.40, N 13.41.
69.07; H 7.03,
N
Found,%: C 13.32.
In the same manner as described in examples 1-10, the compounds of examples 11-86 are prepared.
The physical and chemical properties of the compounds in examples 11-86 are presented in table 4 and 5.
The increased activities of the proposed compounds, along with their reduced side effects, also make them suitable for wide variations, and therefore the invention should not be limited to precisely specified limits. The exact once and daily doses, of course, must be determined according to established medical principles.
In the following experiments, show the effect of the proposed compounds, using metoclopramide chlorohydrate (III HCl) and trimethobenzamide
hydrochloride (II HC1) as reference compounds.
Experiment 1. The compressive effect of test compounds in the isolated ileum of the guinea pig of hartley males weighing approximately 450 g is determined. Prepare intact strips 1.5-2.0 cm long. These preparations are suspended vertically in an organ bath filled with Krebs-Henseleit s solution at 37 ° C, which is saturated with 95% O and 57, C0 g. The rhythmic contractions of the preparations are measured isotonic. Action test
Male hounds weighing approximately 8 kg are fastened overnight. Test compounds (suspended or dissolved in 0.5% CMC) are administered orally and the dogs are fed 45 minutes after. Then, after 15 minutes, 100 mg / kg of apomorphine is applied subcutaneously, and the compounds are estimated as the relative percentage of test compound that has been dissolved in physiological saline.
and see vomiting for 60 minutes.
abbreviations caused by YuM acetylcholine.
The results are shown in table 1.
As a result of this, antiemetic drugs metoclopramide HC1 and
five
0
five
0
five
0
five
0
The results of Table 1 show that Compound 2 has approximately 10-fold and approximately 2.5-fold stronger contractile effect than metoclopramide HC1 and trimethobenzamide. HC1, respectively.
Experiment 2. Improving the effect of the test compound on the suppression of gastrointestinal passage in a mouse induced by dopamine.
Male ddY mice weighing about 22 g were fixed overnight and test compounds were orally administered (suspended in 0.5% carboxymethylcellulose). After 30 minutes, dopamine (2 mg / kg) dissolved in physiological saline, or only physiological saline, is administered intraperitoneally, followed by immediate oral administration of food containing charcoal (5% charcoal powder suspended in 10% gum arabic). After 20 minutes, the animals kill and isolate the digestive tracts from the stomach to the cecum. The gastrointestinal permeability is determined by calculating the total length of the stomach between the pylorus and the cecum and the length to which food containing a corner is taken out of the pylorus. Statistical analysis was performed using Student's t-test for unpaired observations.
The results are shown in table 2.
Thus, the proposed compounds showed a significant improvement in the gastrointestinal permeability, which was inhibited by dopamine at a dose of 30 mg / kg, compared with the anti-emetic drugs metoclopr amide HC1 and trimethobenzamide HC1, which do so to a much lesser extent.
Experiment 3. The suppressive effect of test compounds on hounds, caused by apomorphic.
Male hounds weighing approximately 8 kg are fastened overnight. Test compounds (suspended or dissolved in 0.5% CMC) are administered orally and the dogs are fed 45 minutes after. Then, after 15 minutes, 100 mg / kg of apomorphine dissolved in saline is applied subcutaneously.
As a result of this, antiemetic drugs metoclopramide HC1 and
trimethobenzamide .HCl show significant antiemetic effects at doses of 1 and 30 mg / kg, respectively. Connection shows, however, a weak antiemetic effect at a dose of 30 mg / kg.
Experiment 4. The study of acute toxicology in mice.
Male ICR mice of 5 weeks of age are used for each determination. Test compounds (2-4 different doses) are administered intravenously and values are calculated using the trial and error method.
The results are shown in table 3.
The method of using the proposed compounds includes internal or external use, preferably orally or parenterally, and preferably mixed with a carrier of a pharmaceutical preparation, for example, in the form of any of the above compositions or filled into a capsule to alleviate the treatment conditions and symptoms in a living body. an animal. For example, the compounds can be used in an amount of from about 1.0 to about 1000 mg per day for oral use and from about 1.0 to 500 mg per day for parenteral use. The unit dose, preferably given the appropriate number of times daily in a typical case, is three times.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining benzamide derivatives of the general formula
W-OSGTSN:
45
de RJ is hydrogen, lower alkoxy,
hydroxy, lower alkyl, halogen, amino, nitro, cyano group, sulfamoyl, which may be substituted by lower alkyl 50)
R. - hydrogen, lower alkoxy, hydroxy halogen, amino,
nitro, or R 4 and Re can together form a methylenedioxy group;
RJ - hydrogen, lower alkyl, halogen, aminoJ
R4 and R may have the same or different values, and each of them represents lower alkyl, or R4 and RC can be attached to a nitrogen atom to form 1-pyrrolodinyl or piperidino,
characterized in that the corresponding anhydride, mixed anhydride or acid chloride of the formula
soon
where R ,, Ra and R3 have indicated
meanings
reacted with an amino compound of the general formula
H7NCH2- (J) -OCH 2CH7N
Rt
Rs
20 0
35
40
45
50
where R. and R5 are as defined,
in organic solvent if necessary in the presence of a base.
Priority featured:
09/05/87 R, RI is hydrogen, lower alkoxy and hydroxy, or R, and P together form a methylenedioxy group, Kj is hydrogen, R4 and Py can have the same or different values, and each of them represents lower alkyl, or with a nitrogen atom to form a 1-pyrrolidone or a piperidino group.
09.22.87 R, - lower alkoxy, RЈ represents an amino group, RJ represents halogen.
09.29.87 R, is a sulfamoyl group which can be substituted by lower alkyl, R2 is halogen, RJ is hydrogen and amine, R4 and Helps have the same or different values, and each of them is lower alkyl, and can be combined with nitrogen atom to form 1-pyrrolidinyl or piperidino groups.
05.10.87 R, - lower alkyl, halogen, amino group, which can be substituted by lower alkyl and nitro, R - hydrogen, halogen and nitro groups; RJ is halogen, a R4 and Rf
1516270Й2
may be the same or different and each of them is lower alkyl, and may be
sixteen
united with the nitrogen atom we eat 1-pyrrolidinyl or group.
one
I
A dose that causes a 50% reduction caused by acetylcholine.
dopamic
dopamine
+ dopamine
+ dopamine
+ dopamine
HC1 + dopamine
d "HC1 + dopamine 30
thirty
thirty
thirty
thirty
thirty
thirty
 Significantly different from the groups treated with dopamine, at, 05. Significantly different from the groups treated with dopamine, at, 01
table 2
0
0
0
0
0
0
0
10 12 11 11 12 10 10 10 10 12 13 12 10 10
eleven
22
22
9
22 22 13
| +4.7
53.3t2 31.7 ± 3 43.9 + 2 53.3 + 2 31.7 + 3 44.0 + 4 50.1 + 3 25.0 + 3 43.0 + 6 51.8 ± 1 35.9+ 2 45.2 + 3 54.5 + 3 32.9 + 3 46.5 + 3 50.9 + 2 32.1 ± 2 37.2 + 3 50.9 + 2 32.1 + 2 38.2 + 3
, 0
th
, 0, 2
, 0
, / "-
,about
,
,one
,four
,one
, 0
, 2
,one
, 0
3
56.5 56.9 71.7 58.5 63.4 27.1 32.4
4-KHt 3-CN
. -
3-tBu 3-C1 3-C1 Z-F
Me Hydrochloride In / p needle 171-173C, 8HMN, Ot-2HCl REED (MeOH)
B / c kris- 99-100C ,, H2, N, Ci tall (AcOEt-i r20)
Hydrochloride b / c prisms 155-157С „H g, N} 0g-HC1 rip (EtOH)
B / c Plasti-142-144Cg N, inK ± Oz ya (MezCO-iPr70)
Hydro-B / c needles 132-134С, 9Н g, С1гИ, 02 "
chloride (EtOH) "HC1 1/2 H2O
63-64SmNg, C1g., Og (AcOEt)
W / c prism 80-82C, 8H ,, F, N, Ot (AcOEt)
55.96; , 52; 10.8855.89; 6.69; 10.88
70.57; 6.55; 12.9970.65; 6.51; 12.99
63.42, 6.16; 11.6863.32, 6.14; 11.73
73.20; 8.98; 6.5773.47; 8.96; 6.29
50.54; 5.42; 9.8250.55; 5.51i9.71
58.631 5.68; 10.2959.00; 6.04; 10.19
61.36; 5.44; 7.9561.32; 5.71; 7.98
fj
-four
ON N5 -J O 00 IsJ
81 e-ZOUIN-M 4-Cl H MeMe
82 3-SOcHHs 4-Cl H- (CH4) 4- Yellow oil
83
3-SOfNH-Me 4-Cl I- ((SN)) 4- Celtoe oil
SONNS O-OSNgSN.
five
Table 5
Colorless oil 427, 425 (1: 3)
yellow oil
439, 437 (1: 3)
4.47 (2H, d, J - 5.5 Hz), 6.78 (2H, d. J - 9 Hz), 7.07 (1H, TJ-5.5 Hz), 7.49 (111, l, J - 8.5 Hz), 7.92 (1H, dd, J - -8.5, 2 Hz), 8.32 (1H, d, J - 2 Hz)
16502.32 (6H, s), 2.62 (3N, s), 2.71 (2H, t ,.
(00) J - 5.5 Hz), 4.04 (2H, t, L - 5.5 Hz),
4.54 (2H, fl.J - 5.5 Hz), 5.88 (1H, w), 6.85 (2H, l, J 9 Hz), 7.25 J2H, d, J -9 Hz) , 7.56. ОН, l, J - в.5 Hz), 7.99 (Ш, M, J -8.5, 2 Hz), 8, ЗТ (1Н, д, J -2 Гц)
16441.55-1.97 (4H, m), 2.32-2.72 (4H, m),
(00) 2.87 (2H, t. J - 6 Hz), 4.07 (2H, t,
J - 6 Hz), 4.52 (2H, w), 6.82 J2H, d, J - 9 Hz), 7.09 (2H, dl 9 Hz), 7.36 (1H, d, J - 8 , 5 Hz), 7.70 (W, w), 7.83 (1H, dd, J - 8.5, 2 Hz), 8.34 (1H, d, J - 2 Hz)
about go
j ABOUT
Yu
U)
about
16441.57-1.98 (4n, m), 2.34-2.77 (4H, m),
(C-0) 2.83 (2H, t, J - 5.5 Hz), 4.C8 (2H, t,
J 5.5 Hz), 4.53 (2H, d, J - 5.5 Hz), S, 84 (2H, d, J - 9 Hz), 7.16 OH, w), 7.25 (2H , dd, J - 9 Hz), 7.55 (1H, d, J - 8.5 Hz), 8.03 (1H, dd, J - 8.5, 2 Hz), 8.40 (1H, d J - 2 Hz)
85 p 4-OHB H- (SI4) 4-
86 2-F 4-Р 5-F - (СНС), .- Yellow oil
Light yellow mislo
461
16461.62-1.8 4H, m), 2.45-2.75 (AH, m), 2.83
(C-0) (6H, s), 2.89 (2I, t, J - 6 Hz), 3.96
(ZN, s), 4.10 (2H, TKJ-6 Hz), 4.55 (2H, d. J - 5.5 Hz), 6.88 (2H, d, J - 9 Gd), 7, 05 (1H, d, J "8.5 Hz), 7.27 (2H, d, J - 9 Hz), 8.12 (1H, dd, L-8.5, 2 Hz). 8.22 (1H, d, J - 2 Hz)
"
N
-J O CO N1
1660 1.57-2.10 (4H, m), 2.48-2.80 (4H, m), (C-0) 2.90 (2H, t, J - 6 Hz), 4.10 (2H, t,
J - 6 Hz), 4.48-4.72 (2H, m), 6.67-7.14 (2H, m), 6.89 (2H. D. J 9 Hz), 7.25 (2H, d , J - 9 Hz), 7.73-8.13 (1H, t).

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1627082A3|1991-02-07|Process for preparation benzamide derivatives

---

US7314936B2|2008-01-01|Deazapurines and uses thereof

---

US7087749B2|2006-08-08|Substituted piperidine compounds and methods of their use

---

KR20130019351A|2013-02-26|N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same

---

US5889061A|1999-03-30|Conformationally restricted polyamines

---

EP1263758A2|2002-12-11|3-|-8-azabicyclo[3.2.1]octane derivatives

---

EA007410B1|2006-10-27|N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors

---

BRPI0709466A2|2011-07-19|compound, pharmaceutical composition, method for binding opioid receptors in a patient in need thereof, method for improving organ and cell survival, method for providing cardioprotection, method for reducing anesthesia requirement, method for producing or maintaining an anesthetic state, derivative radio-labeled composite and diagnostic imaging method

---

HUE032761T2|2017-10-30|Process for the preparation of piperazinyl and diazepanyl benzamide derivatives

---

CA1253148A|1989-04-25|1-piperazinecarboxamide derivatives

---

US4076843A|1978-02-28|5,6,7,8-Tetrahydronaphthalene hypotensive agents

---

US5756475A|1998-05-26|Isoprene derivatives

---

EA009292B1|2007-12-28|New pyrrolidines and thiazolidines compounds, a process for their preparation and pharmaceutical compositions containing them

---

AU621003B2|1992-02-27|3-alkoxy-2-aminopropylamides

---

US2830008A|1958-04-08|Amines

---

RU2001914C1|1993-10-30|Method of 4-[3-|-butinyl]-amine and its pharmaceutically acceptable acid-additive salts synthesis

---

KR100382998B1|2003-08-27|6-methoxy-1H-benzotriazole-5-carboxamide derivatives, methods for preparing the same, and pharmaceutical compositions containing the same

---

WO1983001950A1|1983-06-09|1-piperazinocarboxylates, process for their preparation and pharmaceutical compositions containing them

---

JP3888397B2|2007-02-28|Isoprene derivatives

---

KR850001038B1|1985-07-19|Process for preparing allophanoylpiperazine compounds

---

KR20030036834A|2003-05-09|5-phenylbenzylamine compounds, process for their production and intermediates for their synthesis

---

GB1575593A|1980-09-24|Cycloalkylamines

---

JP2004511486A|2004-04-15|Morphinoid derivatives as delta-opioid agonists and antagonists

---

BG104501A|2001-03-30|Urethanes, thio and dithio analogues, the salts thereof, medicaments, containing said compounds, use and method for the production thereof

---

JPH08208643A|1996-08-13|6-methoxy-1h-benzotriazole-5-carboxamide derivative and medicinal composition containing the same

同族专利:

---

公开号 | 公开日

---

HUT47531A|1989-03-28|

---

YU46706B|1994-04-05|

---

DK169816B1|1995-03-06|

---

AU2186288A|1989-03-09|

---

UA6330A1|1994-12-29|

---

AT66913T|1991-09-15|

---

KR940000058B1|1994-01-05|

---

FI884077A|1989-03-06|

---

YU160088A|1990-06-30|

---

KR890005036A|1989-05-11|

---

DK492288A|1989-03-06|

---

FI87644B|1992-10-30|

---

AU606988B2|1991-02-21|

---

ES2037779T3|1993-07-01|

---

BG48932A3|1991-06-14|

---

HU198447B|1989-10-30|

---

US4983633A|1991-01-08|

---

CA1335101C|1995-04-04|

---

FI87644C|1993-02-10|

---

EP0306827A1|1989-03-15|

---

FI884077A0|1988-09-05|

---

EP0306827B1|1991-09-04|

---

DK492288D0|1988-09-05|

---

DE3864636D1|1991-10-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

DE1069640B|1959-11-26|F. Hoffmann-La Roche S. Co. Aktiengesellschaft, Basel |Process for the production of anemetically effective benzylamine derivatives|

---

FR1525M|1961-07-25|1962-11-16|Ile De France|New antiemetic drugs.|

---

NL130752C|1964-05-07|US5864039A|1994-03-30|1999-01-26|Yoshitomi Pharmaceutical Industries, Ltd.|Benzoic acid compounds and use thereof as medicaments|

---

WO1995026953A1|1994-03-30|1995-10-12|Yoshitomi Pharmaceutical Industries, Ltd.|Benzoic acid compound and use thereof as medicine|

---

KR0147963B1|1995-01-10|1998-08-17|강박광|N-arylalkylphenylacetamide derivative and process for the preparation thereof|

---

WO2000028984A1|1998-11-16|2000-05-25|Hokuriku Seiyaku Co., Ltd.|Remedies for digestive tract functional disorder|

---

EP1206446B1|1999-08-07|2004-05-26|Boehringer Ingelheim Pharma GmbH & Co.KG|Carboxylic acid amides, their production and their use as drugs|

---

DE10235312A1|2002-08-01|2004-02-12|Basf Ag|Process for the preparation of aminoalkoxybenzylamines and aminoalkoxybenzonitriles as intermediates|

---

CN1305837C|2004-06-11|2007-03-21|吉林修正药业新药研发中心|Improved prepn process of itopride medicine material|

---

KR100595117B1|2004-07-28|2006-06-30|일양약품주식회사|Process for Preparing 4-[2-DimethylaminoEthoxy]Benzylamine of Itopride·HCl Mediates|

---

ITMI20042168A1|2004-11-12|2005-02-12|Erregierre Spa|PREPARATION PROCESS OF CHLORIDATED ITOPRIDE|

---

KR100663167B1|2005-10-27|2007-01-02|동우신테크 주식회사|Process for preparing itopride hydrochloride|

---

WO2007074386A2|2005-12-28|2007-07-05|Bakulesh Mafatlal Khamar|A novel process for synthesis of itopride and it’s novel intermediate-n--3,4-dimethoxybenzamide|

---

KR100836528B1|2007-07-25|2008-06-10|주식회사 휴온스|Process of manufacturing itopride hydrochloride|

---

CN101967103A|2010-09-28|2011-02-09|浙江金伯士药业有限公司|Novel preparation method of itopride intermediate body|

---

CN103073446B|2011-10-26|2014-12-24|珠海保税区丽珠合成制药有限公司|Preparation method of itopride hydrochloride|

法律状态:
2005-03-10| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: RH4F Effective date: 20041222 |

---

2005-04-10| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: PD4A |

优先权:

---

申请号 | 申请日 | 专利标题

---

JP62221211A|JPS6466153A|1987-09-05|1987-09-05|Amide compound and digestive tract motion-activator containing said compound as active ingredient|

---

JP62236250A|JPS6479144A|1987-09-22|1987-09-22|Amide compound and agent for promoting motion of digestive tract containing said compound|

---

JP62242765A|JPS6485960A|1987-09-29|1987-09-29|Amide compound and reactivator for motion of digestive tube comprising said compound as active ingredient|

---

JP62249749A|JPH0193568A|1987-10-05|1987-10-05|Amide compound and enterokinesis-activation agent containing said compound as active component|

---